Form D · Pharmaceuticals
Potenza Therapeutics, Inc.
Cambridge, MA · CIK 0001627187
Offering snapshot reported Dec 29, 2017 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 19, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 29, 2017 | Initial | $5,000,000 | No comparison | 5 | SEC filing |
| Mar 17, 2016 | Amendment | $30,000,000 | $15,000,000vs Dec 5, 2014 | 6 | SEC filing |
| Dec 5, 2014 | Initial | $15,000,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-301945
Source: Form D, filed Dec 29, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sakae Asanuma | Director |
| David Cordo | Executive |
| Luke Evnin | Director |
| Phil Gutry | Director |
| Daniel Hicklin | Director, Executive |
| Reid Leonard | Executive |
| Shunichiro Matsumoto | Director |
| Arnold Oronsky | Director |
| Cynthia Seidel Dugan | Executive |
| James Wescott | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1030 Masssachusetts Avenue Suite 210
Cambridge, MA, 02138
Cambridge, MA, 02138